TGFB1 and Hepatic fibrosis: Regarding the treatment of hepatic fibrosis, it has been shown that JNK inhibitors downregulate TGF-β and PDGF expression, affecting the activation of mouse primary HSCs and downregulating TGF-β and PDGF expression in human HSCs101.